Home » Topics » BioWorld Science

BioWorld Science
RSS

Disulfiram/copper gluconate studied in phase I for treatment-refractory multiple myeloma

May 31, 2021

RNF6 and SF3B2 are novel therapeutic targets in colorectal cancer

May 31, 2021

Phase I trial explores use of BIVV-001 in adults with type 2N and 3 von Willebrand disease

May 31, 2021

Enrollment opens in phase IIb study of ARO-APOC3 in severe hypertriglyceridemia

May 31, 2021

BPRCX-807 demonstrates promising activity in models of HCC

May 31, 2021

NIDA studies TRV-734 in phase II for opioid use disorder

May 31, 2021

Phase I trial investigates MT-6402 in PD-L1-expressing advanced solid cancer

May 31, 2021

Ziltivekimab reduces biomarkers of inflammation and thrombosis in phase II RESCUE study

May 31, 2021

Affibody describes new compounds for HMGB1-related disorders

May 31, 2021

Nanjing Sanhome Pharmaceutical synthesizes PTPN11 inhibitors

May 31, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...